Anti-Obesity Hydrogel Tech Absorbs $30m

Gelesis has raised $30m to support the company's activities as it readies its Gelesis100 hydrogel-based anti-obesity treatment for US and EU regulatory approval submissions this year and lays the groundwork for commercialization.

Overweight

Having closed a $30m financing round, Gelesis is now planning to submit its anti-obesity hydrogel pill for US pre-market approval and CE mark authorization this year and start preparing for commercialization.

Gelesis100 is the first product to emerge from Gelesis' hydrogel platform. The product consists of orally-administered capsules, each containing small hydrogel particles made from two natural components that form a...

More from Gastroenterology

More from Device Area